Skip to main content

Table 1 Cancer specific survival (CSS) and clinicopathological findings in 162 patients operated with radical nephrectomy for clear cell renal cell carcinoma; multivariate analysis

From: Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

  Cancer specific survival (CSS)
  HR 95% CI p-value
PAI-1 expression    
No or low (ref.)    
Medium/High 2.92 1.15 - 4.87 0.020
TNM stage group    < 0.001
I ref.    
II 2.52 0.75 - 7.56 8.74
III 2.99 1.11 - 7.56 0.030
IV 11.60 4.27 - 31.44 < 0.001
Microvessel Density    
Low (ref.)    
High 2.19 1.24 - 3.85 0.007
TSP-1    
High (ref.)    
Low 3.69 1.74 - 7.81 0.001
Nuclear grade    
(1+2) (ref.)    
(3+4) 1.29 0.76 - 2.18 0.341
Continuously coded    
Tumour size 1.01 0.92 - 1.11 0.837